Optimizing recovery from aplasia after high-dose therapy and hematopoietic stem cell transplantation

Abstract

Objective. Discussion of the roles of hematopoietic growth factors and the role of stem cells in shortening aplasia after transplant. In addition, the role of the treatment regimen in determining the length of aplasia.

Data Sources. A series of original research stud ies from H. Lee Moffitt Cancer center which was published from 1993 to the present. In addition, selected references were reviewed and quoted to support selective arguments.

Study Selection. Since 1989 data from four allo cated, parallel, high-dose phase I/II trials conducted at H. Lee Moffitt Cancer Center, Tampa, Fla and include the following treatment regimens: (1) ifosfamide, carbo platin, and etoposide (ICE); (2) mitoxantrone and thio tepa (MITT); (3) busulfan and cyclophosphamide (BUCY2); and (4) Taxol, Novantrone, thiotepa (TNT). The results of hematopoietic recovery from consecutive patients allocated on these trials will be discussed.

Data Extraction. Granulocyte engraftment was defined as having occurred when an absolute granu locyte count of 500/μL has been surpassed on 3 or more consecutive days. The period of aplasia was defined as the number of days from the day of stem cell infusion to the day of engraftment. The period of granulocyte engraftment and aplasia was examined comparatively as a function of the source of stem cells given to the patient at their initial reinfusion. Time to engraftment was evaluated by Kaplan-Meier Product Limit Method and probability curves were compared by logrank analysis.

Data Synthesis. The duration of aplasia after high-dose therapy and stem cell transplantation deter mines the risk of opportunistic infection and the cost of the transplant. Prospective, randomized, controlled trials for both sargramostim and filgrastim have clearly demonstrated a significantly shorter period of aplasia produced by high-dose therapy by several days. From sequential comparison trials, it appears that filgrastim may be superior to sargramostim in shortening aplasia after bone marrow stem cell transplantation following high-dose therapy. Erythropoietin, while not shorten ing the period of aplasia, has been demonstrated to reduce erythrocyte transfusion requirements; whereas the question about cost-effectiveness remains to be unanswered. In comparing granulocyte recovery of bone marrow stem cell transplants with peripheral blood stem cell transplants, both perform similarly, especially, if collected under identical stimulatory conditions. Both the mobilizing regimen and the treatment regimen, but not the anatomic compart ment, are significant factors which determine the speed of engraftment after high-dose therapy and hematopoietic stem cells are transplanted.

Conclusions. The purpose of high-dose therapy is to improve the cure rate for selected malignancies. Shortening aplasia can reduce the death rate from infections but only has a marginal impact on the cure rate as the death rate is relatively low. It behooves us, then, to develop the best treatment and with that regimen determine how best to shorten the period of aplasia.

Keywords

Recovery aplasia high dose;stem cell.

Get full access to this article

View all access options for this article.

References

Korbling M.

Burke P.

Braine HG

et al.

Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol.1981;9:684-690.

Brenner MK

Rill DR

Moen RC

et al.

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation . Lancet.1993;341:85.

Fields KK

Elfenbein GJ

Perkins JB

, et al. High-dose ifosfamide/carboplatin/etoposide: Maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion . Semin Oncol.1994;21 (suppl 12):86-92.

Rolston KV

Rubenstein EB

Freifield A.

Early empiric antibiotic therapy for febrile neutropenia patients at low risk . In:

Greene JN

and

Hiemenz JW

, eds. Infectious Disease Clinics of North America: Infectious Complications of Cancer Therapy. Philadelphia : WB Saunders; 1996, pp 223-237.

Spitzer G.

Adkins DR

Spencer V.

, et al. Randomized study of growth factors postperipheral-blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol.1994;12: 661-670.

Nemunaitis J.

Rosenfeld CR

Ash R.

, et al. Phase II, double blind placebo controlled trial of rhGM-CSF following allogeneic bone marrow transplant. Bone Marrow Transplant.1995;15:949-954.

Sheridan WP

Begley CG

Juttner CA

et al.

Effect of peripheral-blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating-factor for hematologic support after high-dose intensification for breast cancer. Blood.1992;79:3036-3044.

Beyer J.

Schwella N.

Zingsern J.

, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison . J Clin Oncol.1995; 12:1328-1335.

Janssen WE

Smilee RC

Elfenbein GJ

A prospective randomized trial comparing blood vs marrow derived stem cells for hematopoietic replacement following high dose chemotherapy. J Hemother.1995; 4:139-140.

10.

Elfenbein GJ

Hematopoietic stem cells for transplantation: Marrow or peripheral blood? Cancer Control.1994;1:88-189.

11.

Peters WP

Rosner G.

Ross M.

et al.

Comparative effects of granulocyte-macrophage colony-stimulating factors and granulocyte colony-stimulating factor on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood.1993;81:1709-1919.

12.

Broun ER

Gorin R.

Kneebone P.

, et al. Randomized trial of the addition of peripheral blood progenitor cells to autologous bone marrow in patients undergoing high-dose chemotherapy with autologous progenitor support for breast and germ cell cancer. Proc ASCO.1994;13:A1486.

13.

Shivers SC

Carter R.

Elfenbein GJ

Janssen WE

Synergy between bone marrow (BM) cells and peripheral blood stem cells (PBSC) in the ability to form granulocyte/monocyte colony forming units (CFU-GM) in vitro. Exp Hematol.1994;22: 758.

14.

Perkins JB

Elfenbein GJ

Janssen WE

et al.

Lack of difference in rate of hematopoietic recovery after bone marrow and peripheral blood stem cell infusion versus peripheral blood stem cells alone . Exp Hematol.1995;23:761.

15.

Elfenbein GJ

Janssen WE

Perkins JB

Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man: Review of results from autologous stem cell transplant trials and laboratory studies at the moffitt cancer center . In:

Sackstein R

Janssen WE

, and

Elfenbein GJ

, eds. Bone Marrow Transplantation: Foundations for the 21st Century . New York: The New York Academy of Sciences; 1995, pp 315-338.

16.

Elfenbein GJ

Perkins JB

Fields KK

, et al. Hematologic recovery after high dose Taxol, Novantrone, Thiotepa (TNT) and autologous stem cell transplant: Evaluation of the effects of stem cell source and Taxol. Blood.1994;84 (suppl 1):707a.

17.

Fields KK

Perkins JB

Elfenbein GJ

Reply to Letter-to-the-Editor. J Clin Oncol.1995;13:1826-1827.

18.

Fennelly D.

Vahdat L.

Schneider J.

, et al. High-intensity chemotherapy with peripheral blood progenitor cell support. Semin Oncol.1994;21 (suppl 2):21-25.

19.

Fields KK

Elfenbein GJ

Lazarus HM

et al.

Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: Toxicity profile. J Clin Oncol.1995;13:3223-3332.

20.

Fields K.

Perkins J.

Elfenbein GJ

, et al. A phase I dose escalation trial of high dose TAXOL, NOVANTRONE and thioTEPA (TNT) followed by autologous stem cell rescue (ASCR): Toxicity . Proc ASCO.1995;14: 322.

21.

Tutschka PJ

Santos GW

Elfenbein GJ

Marrow transplantation in acute leukemia following busulfan and cyclophosphamide . In:

Thierfelder S

Rodt H

Kolb HJ

, eds Immunobiology of Bone Marrow Transplantation. New York: Springer, 1980; Suppl 25 to BLUT; 375-380.

22.

Fields KK

Elfenbein GJ

Perkins JB

, et al. Two novel high dose treatment regimens for metastatic breast cancer: Ifosfamide, carboplatin plus etoposide (ICE) and mitoxantrone plus thiotepa (MITT): Outcomes and toxicities. Semin Oncol.1993;20 (suppl 6):59-66.